Related scientific articles (all)

Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges.

Authors : Alameddine RS, Otrock ZK, Awada A, Shamseddine A
Year : 2013
Journal : Curr Opin Oncol
Volume : 25(3)
Pages : 313-24

Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .

Authors : Zardavas D, Cameron D, Krop I, Piccart-Gebhart M
Year : 2013
Journal : Am Soc Clin Oncol Educ Book
Volume : null(null)

Emerging targeted agents in metastatic breast cancer.

Authors : Zardavas D, Baselga J, Piccart-Gebhart M
Year : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(4)
Pages : 191-210

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.

Authors : Ades F, Senterre C, de Azambuja E, Sullivan R, Popescu R, Parent F, Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2897-902

Stratified Medicine: a call for action

Authors : Awada A, Annemans L, Broeckx D, Pauwels P, Simoens S, Van Belle S, van Cutsem E, Van Hoof E, De Greve J
Year : 2013
Journal : Belgian J Medical Oncology
Volume : 7(1)
Pages : 15-19

Academic versus industry-driven research in upper gastrointestinal cancer: sinners and saints.

Authors : Hendlisz A, Charette N, Awada A, Deleporte A
Year : 2013
Journal : Curr Opin Oncol
Volume : 25(4)
Pages : 407-8

Personalized therapy for breast cancer: a dream or a reality?

Authors : Zardavas D, Pugliano L, Piccart-Gebhart M
Year : 2013
Journal : Future Oncol
Volume : 9(8)
Pages : 1105-19

Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial.

Authors : Azim HA, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG, Smith I, Jackisch C, Kim SB, Aktas B, Huang CS, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart-Gebhart M, de Azambuja E
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(36)
Pages : 4504-11

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

Authors : Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart-Gebhart M
Year : 2013
Journal : Eur. J. Cancer
Volume : 49(12)
Pages : 2621-32

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial.

Authors : Azim HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M
Year : 2013
Journal : Breast
Volume : 22(6)
Pages : 1060-5

Personalised cancer management: closer, but not here yet.

Authors : Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1951-5

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

Authors : Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, + collaborators (among others :, Hannah AL, Perez EA
Year : 2013
Journal : Lancet Oncol
Volume : 14(12)
Pages : 1216-25

Stratified medicine: a call for action.

Authors : Jacob I, Awada A, Payne K, Annemans L
Year : 2013
Journal : Expert Rev Pharmacoecon Outcomes Res
Volume : 13(3)
Pages : 277-9

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Authors : Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart-Gebhart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS
Year : 2013
Journal : Adv Ther
Volume : 30(10)
Pages : 870-84

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

Authors : de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, Dhondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A
Year : 2013
Journal : Ann Oncol
Volume : 24(12)
Pages : 2985-9

Breast Cancer. Side Effects of Medical Cancer Therapy: Prevention and Treatment. Ed. Mario A. Dicato. Chapter 2: P29-117; Springer 2013, XIII.

Authors : Aftimos P, Gombos A, Pugliano L, Awada A, Piccart-Gebhart M
Year : 2013
Journal : Book
Volume : chapter2
Pages : P29-117

Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.

Authors : Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart-Gebhart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA
Year : 2013
Journal : Curr Med Res Opin
Volume : 29(11)
Pages : 1463-73

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.

Authors : Borbath I, Ceratti A, Verslype C, Demols A, Delaunoit T, Laurent S, Deleporte A, Vergauwe P, Van Maanen A, Sempoux C, van Cutsem E, Van Laethem JL
Year : 2013
Journal : Ann Oncol
Volume : 24(11)
Pages : 2824-9

Histiocytose agressive à cellules de Langerhans 20 ans après un cancer du sein : à propos d’un cas.

Authors : Zakkouri F, Klastersky J, Alexiou J, de Saint-Aubain de Somerhausen N, Flamen P, Firescu R, Georgala A, Awada A
Year : 2013
Journal : J Am Soc Echocardiogr
Volume : 5
Pages : 220-223

Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.

Authors : Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart-Gebhart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M
Year : 2013
Journal : Clin Breast Cancer
Volume : 13(6)
Pages : 421-432.e8